Anticancer research
-
Anticancer research · Jan 2006
Case ReportsBoth bronchial and vascular stenting followed by chemoradiotherapy for locally advanced non-small cell lung cancer.
Airway and vascular constrictions are expected problems for lung cancer patients. The clinical course of a patient in whom stents were inserted in 3 constriction regions is reported. ⋯ Within 5 months of treatment, complete local control was achieved and there was no reconstriction. Both endobronchial and endovascular stenting prior to antitumor therapy may be beneficial in the treatment of locally advanced cases of lung cancer.
-
Anticancer research · Jan 2006
HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
The aim of this prospective study was to investigate whether there were changes in HER-2/neu status in newly-developed metastatic lesions following treatment with trastuzumab in advanced breast cancer patients overexpressing HER-2/neu. The utility of serological assays for HER-2/neu in such patients was also studied. ⋯ These data suggest that, for most patients with metastatic breast cancer treated with trastuzumab, the HER-2/neu expression as measured by IHC and/or CISH in newly-developed metastatic lesions was unchanged. However, a remarkable percentage of cases lost HER-2/neu overexpression. It is not clear whether this finding implies resistance or sensitivity to trastuzumab.
-
Anticancer research · Jan 2006
EGFR, c-erbB-2 and ki-67 in NSCLC and preneoplastic bronchial lesions.
The relationships between EGF-R and c-erbB-2 with other factors involved in tumour regulation are not well understood. The aim of this study was to correlate the expression of these markers with tumour proliferation. ⋯ EGF-R and c-erbB-2 do not seem to be correlated with Ki-67 in NSCLC.